Best Review Article Award
Stavros derdas
Aegean College
Stavros derdas is a researcher affiliated with research activity in the area of cancer biomarkers. The supplied bibliometric record identifies 17 documents, 487 citations, and an h-index of 9 under Scopus Author ID 6505579887. These indicators provide a bibliometric description of the research record and should be interpreted in the context of publication field, document type, citation practices, and database coverage. [1]
Abstract
This academic recognition profile presents STAVROS DERDAS in connection with the Best Review Article Award and the subject area of Cancer Biomarker. The profile is based on the supplied institutional and bibliometric information, including affiliation with AEGEAN COLLEGE, Greece, Scopus Author ID 6505579887, 17 documents, 487 citations, and an h-index of 9. Cancer biomarkers constitute an important research domain within contemporary oncology because biomarkers may support risk assessment, screening, diagnosis, prognosis, treatment-response prediction, and disease monitoring. Their translation into clinical practice requires analytical validation, clinical validation, and assessment of clinical utility. [2] Contemporary research additionally encompasses genomic, transcriptomic, proteomic, circulating, and liquid-biopsy approaches, with continuing emphasis on reproducibility and clinical validation. [3]
Keywords
STAVROS DERDAS; Cancer Biomarker; Cancer Research; Oncology; Biomarker Discovery; Biomarker Validation; Precision Oncology; Diagnostic Biomarkers; Prognostic Biomarkers; Molecular Oncology; Research Review; Academic Research.
Introduction
Cancer biomarker research covers the identification and evaluation of measurable biological characteristics associated with cancer risk, detection, classification, prognosis, treatment response, or disease progression. The field has developed alongside advances in molecular biology, genomics, proteomics, imaging, immunology, and analytical technologies. Reviews of cancer biomarkers emphasize that a candidate biomarker must be evaluated systematically before it can be considered suitable for routine clinical application. [2]
Recent literature describes an expanding biomarker landscape involving conventional protein markers as well as genomic and transcriptomic targets, circulating tumour DNA, circulating tumour cells, microRNAs, and liquid-biopsy technologies. These developments have broadened the possibilities for early detection, molecular characterization, prognosis, treatment selection, and disease monitoring, while also creating requirements for robust validation and reproducibility. [4]
Research Profile
The supplied research profile identifies STAVROS DERDAS with AEGEAN COLLEGE in Greece and associates the researcher with Cancer Biomarker as the principal subject area for this recognition profile. The Scopus information supplied for the profile records 17 documents, 487 citations, and an h-index of 9. Scopus author metrics are database-dependent and can change as publications are indexed, records are corrected, and citations are added. [1]
Research Contributions
The research area represented in this profile is situated within the broader field of cancer biomarker science. Biomarker research can encompass the identification of measurable molecular or biological characteristics, development of analytical assays, assessment of diagnostic or prognostic performance, evaluation of treatment-response indicators, and investigation of biomarkers for disease surveillance. Established literature stresses the distinction between analytical validity, clinical validity, and clinical utility when evaluating candidate biomarkers. [2]
- Cancer biomarker research connects molecular characteristics with clinically relevant questions involving detection, diagnosis, prognosis, treatment response, and monitoring.
- Modern biomarker discovery increasingly incorporates genomic, transcriptomic, proteomic, and circulating molecular information. [4]
- Biomarker development requires appropriate analytical and clinical validation before translation into clinical practice. [2]
- Emerging detection platforms include liquid biopsy and biosensor-based approaches, which continue to be evaluated for sensitivity, specificity, portability, and clinical applicability. [5]
Publications
The supplied Scopus profile records 17 documents associated with Scopus Author ID 6505579887. The available information does not provide a verified publication-by-publication bibliography for STAVROS DERDAS; therefore, individual publications are not attributed to the researcher in this article without documentary confirmation. The document count is presented as a bibliometric profile indicator rather than as a substitute for a complete publication list. [1]
For contextual purposes, peer-reviewed literature demonstrates the breadth of the cancer biomarker field. Reviews have examined biomarker development, emerging genomic and molecular approaches, biosensor technologies, and the clinical implications of biomarker-guided precision oncology. [2] [3] [5]
Research Impact
The supplied bibliometric record reports 487 citations across 17 documents and an h-index of 9. These figures indicate citation activity associated with the identified Scopus author record, while their interpretation should take into account disciplinary citation patterns, publication types, database coverage, and the timing of indexing. [1]
Within cancer research, biomarker studies can contribute to translational research by providing measurable indicators for biological characterization and clinical decision-making. Contemporary reviews emphasize the continuing movement from conventional protein-based markers toward integrated genomic, transcriptomic, proteomic, and liquid-biopsy approaches. [3] [4] The scientific impact of individual biomarker research ultimately depends on factors such as reproducibility, independent validation, clinical relevance, methodological quality, and successful translation.
Award Suitability
The Best Review Article Award is presented here in relation to the research profile supplied for STAVROS DERDAS, with Cancer Biomarker identified as the relevant subject area. The profile contains bibliometric evidence of scholarly activity, including 17 documents, 487 citations, and an h-index of 9. [1] The suitability of a review-article recognition should additionally be assessed against the specific award’s formal criteria, including the documented review article or articles, originality and synthesis of the literature, methodological rigor, scholarly contribution, relevance to oncology and cancer research, and evidence supporting the submitted work.
The associated event is the International Research Awards on Oncology and Cancer Research. The event website describes the awards as recognizing researchers, scientists, academicians, healthcare professionals, and innovators working across areas including oncology, cancer therapy, precision medicine, immunotherapy, and translational science. [6] The award profile should therefore be understood as an academic recognition page based on the supplied researcher information rather than as an independent assessment of the researcher’s complete scholarly record.
Conclusion
STAVROS DERDAS, affiliated with AEGEAN COLLEGE in Greece, is represented in this profile within the research area of Cancer Biomarker. The supplied Scopus information records 17 documents, 487 citations, and an h-index of 9 under Author ID 6505579887. Cancer biomarker research remains an interdisciplinary area involving molecular discovery, analytical development, clinical validation, and translational oncology. [2] [3] The Best Review Article Award recognition is contextualized by this documented research profile and by the broader relevance of biomarker research to oncology and cancer research.
External Links
References
- Elsevier. (n.d.). Scopus author details: STAVROS DERDAS, Author ID 6505579887. Scopus.https://www.scopus.com/authid/detail.uri?authorId=6505579887
- Henry, N. L., & Hayes, D. F. (2012). Cancer biomarkers. Molecular Oncology, 6(2), 140–146. DOI: 10.1016/j.molonc.2012.01.010.https://doi.org/10.1016/j.molonc.2012.01.010
- Passaro, A., et al. (2024). Cancer Biomarkers: Emerging Trends and Clinical Implications for Personalized Treatment. Cell, 187(7), 1617–1635. DOI: 10.1016/j.cell.2024.02.041.https://doi.org/10.1016/j.cell.2024.02.041
- Basheeruddin, M., Qausain, S., Anjankar, A., & Khan, F. I. (2026). Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer. Oncology Reviews, 20, 1809836. DOI: 10.3389/or.2026.1809836.https://doi.org/10.3389/or.2026.1809836
- Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry, 158, 116813 (2023). DOI: 10.1016/j.trac.2022.116813.https://doi.org/10.1016/j.trac.2022.116813
- Pencis. (n.d.). International Research Awards on Oncology and Cancer Research. Pencis.https://oncology.pencis.com/